Neurological conditions and diseases impose an enormous clinical and social burden globally, and affect approximately 200 million people in the U.S., Europe and Japan (according to Business Insights analysis). These include acute trauma or ischemic injury conditions such as stroke, traumatic brain injury, and spinal cord injury, as well as episodic, chronic or progressive neurological conditions like depression, schizophrenia, epilepsy, Parkinson’s Disease, Multiple Sclerosis, Alzheimer’s Disease, migraine, ADHD and other conditions. For many neurological conditions there are few effective therapeutic options available, and the field is an intense area of research and development among major pharmaceutical and biotechnology companies.
We believe that MultiStem® could have broad relevance for treating acute neurological conditions and injuries, such as stroke, traumatic brain injury (TBI), neonatal hypoxic ischemia, and possibly spinal cord injury, as well as chronic neurological conditions that involve inflammation and neurodegeneration, such as Multiple Sclerosis and possibly Parkinson’s disease. In preclinical studies, administration of MultiStem in various models of neurological injury has shown the potential to reduce inflammatory mediated damage, and enhance tissue repair and healing, such as promoting repair of the blood brain barrier.
Specifically, we believe that MultiStem may provide a benefit in certain neurological conditions in several ways, such as by protecting damaged or injured neurons, reducing inflammation, promoting formation of new blood vessels, and by augmenting tissue repair in healing. We are working with multiple independent labs to evaluate the potential application of MultiStem in a range of neurological conditions.